Abbvie Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has one hundred and thirty-nine approved drugs.

There are two hundred and thirty US patents protecting ABBVIE drugs.

There are two thousand seven hundred and thirty-one patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-five supplementary protection certificates in nineteen countries.

Summary for Abbvie

International Patents:	2731
US Patents:	230
Tradenames:	125
Ingredients:	99
NDAs:	139
Drug Master File Entries:	1
Patent Litigation for Abbvie:	See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes	11,246,866*PED	⤷ Sign Up			Y	⤷ Sign Up
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No	11,110,087	⤷ Sign Up				⤷ Sign Up
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	8,772,325	⤷ Sign Up				⤷ Sign Up
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes	8,685,930	⤷ Sign Up	Y		Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Abbvie

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	ACZONE	dapsone	GEL;TOPICAL	021794-001	Jul 7, 2005	5,863,560	⤷ Sign Up
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-001	Jul 28, 1997	6,080,428	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-008	Aug 15, 2011	5,480,656	⤷ Sign Up
Abbvie	BIAXIN XL	clarithromycin	TABLET, EXTENDED RELEASE;ORAL	050775-001	Mar 3, 2000	6,552,616	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Capsules	1 mcg and 2 mcg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	135 mg	➤ Subscribe	2009-09-01
➤ Subscribe	Topical Solution	0.03%	➤ Subscribe	2010-05-03
➤ Subscribe	Tablets	400 mg and 600 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-08-16
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19
➤ Subscribe	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	➤ Subscribe	2009-08-04
➤ Subscribe	Suppository	1000 mg	➤ Subscribe	2013-05-24
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg	➤ Subscribe	2013-06-17
➤ Subscribe	Tablets	5 mg/200 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Injection	400 mg/vial and 600 mg/vial	➤ Subscribe	2014-10-29
➤ Subscribe	Extended-release Tablet	500 mg	➤ Subscribe	2010-12-06
➤ Subscribe	Capsules	14 mg/10 mg and 28 mg/10 mg	➤ Subscribe	2015-05-18
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-23
➤ Subscribe	Extended-release Tablets	500 mg	➤ Subscribe	2005-02-08
➤ Subscribe	Capsules	7 mg/10 mg	➤ Subscribe	2016-09-26
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-12-20
➤ Subscribe	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	➤ Subscribe	2007-11-09
➤ Subscribe	Oral Solution	80 mg/20 mg per mL	➤ Subscribe	2014-06-19
➤ Subscribe	Ophthalmic Solution	0.2%/0.5%	➤ Subscribe	2008-11-21
➤ Subscribe	Extended-release Tablets	4 mg/ 240 mg	➤ Subscribe	2007-07-24
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Ophthalmic Solution	0.03%	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	1 mg, 2 mg and 4 mg	➤ Subscribe	2004-10-04
➤ Subscribe	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	➤ Subscribe	2008-11-28
➤ Subscribe	Delayed-release Capsules	45 mg	➤ Subscribe	2009-09-02
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2010-12-07
➤ Subscribe	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	➤ Subscribe	2013-01-14
➤ Subscribe	Capsules	4 mcg	➤ Subscribe	2008-08-25
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Gel	10%	➤ Subscribe	2014-06-19
➤ Subscribe	Extended-release Capsules	28 mg	➤ Subscribe	2013-06-12
➤ Subscribe	Injection	10 mg/mL (2 mL)	➤ Subscribe	2018-07-13
➤ Subscribe	Tablets	2.5 mg/200 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2009-08-12
➤ Subscribe	Delayed-release Tablets	800 mg	➤ Subscribe	2011-07-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-06-10
➤ Subscribe	Tablets	10 mg, 20 mg, and 40 mg	➤ Subscribe	2015-01-21
➤ Subscribe	Ophthalmic Solution	0.40%	➤ Subscribe	2005-01-28
➤ Subscribe	Extended-release Tablets	250 mg	➤ Subscribe	2004-05-03
➤ Subscribe	Capsules	21 mg/10 mg	➤ Subscribe	2016-09-23
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-24
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	100 mg/25 mg	➤ Subscribe	2008-12-23
➤ Subscribe	Ophthalmic Solution	0.15%	➤ Subscribe	2006-11-03
➤ Subscribe	Extended-release Tablets	1 mg/240 mg	➤ Subscribe	2008-02-20
➤ Subscribe	Capsules	145 mcg and 290 mcg	➤ Subscribe	2016-08-30
➤ Subscribe	Ophthalmic Solution	0.25%	➤ Subscribe	2014-07-30
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2017-06-09
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Delayed-release Capsules	400 mg	➤ Subscribe	2014-06-17
➤ Subscribe	Ophthalmic Solution	0.01%	➤ Subscribe	2011-04-05

International Patents for Abbvie Drugs

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Brazil	102018002956	⤷ Sign Up
European Patent Office	3062775	⤷ Sign Up
Spain	2525021	⤷ Sign Up
Denmark	2558081	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Abbvie Drugs

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758590	CA 2017 00067	Denmark	⤷ Sign Up	PRODUCT NAME: DEOXYCHOLSYRE NATRIUMSALT; NAT. REG. NO/DATE: 59040 20170703; FIRST REG. NO/DATE: IS IS/1/16/071/01 20160729
1594517	PA2013013	Lithuania	⤷ Sign Up	PRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
2435432	LUC00020	Luxembourg	⤷ Sign Up	PRODUCT NAME: VENETOCLAX (VENCLYXTO); AUTHORISATION NUMBER AND DATE: EU/1/16/1138 20161207
1043327	300568	Netherlands	⤷ Sign Up	PRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for Abbvie

Paragraph IV (Patent) Challenges for ABBVIE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing